Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Orthopaedics companies’ nightmare quarter
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The next orthopaedics megamerger
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Medtronic spends $1.6bn to finish what it started with Mazor
The industry leader’s biggest buy since Covidien gets it into robots, but direct competition with Intuitive is unlikely.
New filler approved, but Wright can’t match Medtronic
Wright's bone filler sales are growing fast, but Medtronic still rules.
Lack of takeovers sees medtech hiring staff again
Intuitive Surgical is the winner in terms of sales per employee, despite increasing its headcount 17%.
